BGMS

#4898
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
0.86
0.86
Year Range
0.57
6.70
Daily Change
-3.37%
Monthly Change
-1.15%
6 month change
-10.06%
Year Change
-85.67%
Previous Close
0.8 9
Open
0.8 6
Low
0.8 6
High
0.8 6
Volume
3
Open full chart

Financials

Overview Statement Statistics Dividends Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q2 FY2012

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. on May 15, 2012, regarding events occurring on May 14, 2012. The filing serves as soliciting material pursuant to Rule 14a-12 under the Exchange Act. The company is incorporated in Delaware and maintains its principal executive offices in Berkeley Heights, NJ.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions rather than financial performance data.

Material Changes and Corporate Actions

On May 14, 2012, the Company mailed a letter to stockholders enclosing an additional proxy card for the annual meeting scheduled for May 23, 2012. The filing highlights the following critical proposals:

  • Reverse Stock Split: Approval of a reverse stock split in a ratio of up to and including 1:10. The Board of Directors will determine the specific ratio. This action is intended to enable the Company to regain compliance with the minimum per share bid price requirement and continue its listing on The NASDAQ Global Market.
  • Equity Incentive Plan: Approval to amend the 2006 equity incentive plan to increase the number of shares available for grant by 4.8 million shares (on a pre-split basis).
  • Director Election: Election of directors.
  • Accounting Firm: Ratification of the appointment of an independent registered public accounting firm.

Guidance, Outlook, and Risks

The filing does not contain forward-looking financial guidance or management commentary on operational outlook. The primary risk identified is the potential loss of listing on The NASDAQ Global Market due to non-compliance with the minimum per share bid price requirement, which the proposed reverse stock split aims to mitigate.

Investor Verification Checklist

  • Verify the specific reverse stock split ratio to be determined by the Board of Directors.
  • Confirm the outcome of the May 23, 2012 annual meeting regarding the reverse stock split and NASDAQ compliance.
  • Review the attached Exhibit 99.1 (letter to stockholders) for detailed voting instructions.
  • Monitor the Company's stock price to assess the effectiveness of the reverse split in maintaining NASDAQ listing status.